Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 4/20 | 0.44 |
| ▸ | MMP2 | P08253 | 5/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 2/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 3/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6432712 | 0.87 | PLAU (0.46) | PLAUPOLBMAPTALDH1A1PLG | |
| SCHEMBL6435266 | 0.86 | PLAU (0.46) | PLAUALDH1A1PLGPLAT | |
| SCHEMBL6433840 | 0.86 | PLAU (0.46) | PLAUPLGPLATBCL2MCL1 | |
| SCHEMBL7405965 | 0.86 | BACE1 (0.44) | PLAUPOLBMAPTALDH1A1PLG | |
| SCHEMBL6433798 | 0.84 | PLAU (0.49) | PLAUPLGMMP2PLATMEN1 | |
| SCHEMBL6434806 | 0.83 | PLAU (0.54) | PLAUPOLBMAPTALDH1A1PLG | |
| SCHEMBL6436550 | 0.82 | PLAU (0.58) | PLAUPLGPLATMMP9 | |
| SCHEMBL6435278 | 0.81 | ROCK2 (0.53) | POLBMAPTALDH1A1TDP1MEN1 | |
| SCHEMBL6435282 | 0.81 | ROCK2 (0.53) | POLBMAPTALDH1A1TDP1MEN1 | |
| SCHEMBL6432675 | 0.81 | PLAU (0.56) | PLAUMAPTALDH1A1PLGMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1172400-B1 | THERMOPLASTIC RESIN FILM WITH SATISFACTORY PRINTABILITY | YUPO CORP (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| US-6586106-B2 | Ink transfer, adhesion and aging stability, and being satisfactory in back ghost when offset printing using oxidation polymerization type ink is performed on both faces | YUPO CORPORATION (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| US-20020054991-A1 | Thermoplastic resin film satisfactory in printability | YUPO CORPORATION (JP) | 2002-05-09 | — | — | US | disclosed |
| EP-1172400-A1 | THERMOPLASTIC RESIN FILM WITH SATISFACTORY PRINTABILITY | Yupo Corporation (JP) | 2002-01-16 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| EP-1077945-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
| WO-2000005214-A2 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLAU 119/4885POLB 476/4885MAPT 2392/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLAU 119/4885POLB 476/4885MAPT 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.